AstraZeneca Drops $2B on Summit Therapeutics Stake to Build Next-Gen Cancer Combos

AstraZeneca announced a $2B equity investment and clinical collaboration with Summit Therapeutics, securing a roughly 12% stake in the biotech company. Summit's lead drug, ivonescimab, is a first-in-class bispecific antibody that attacks cancer through two pathways (PD-1 and VEGF) simultaneously. The medication recently outperformed Merck's Keytruda—one of the highest-grossing drugs in history—in head-to-head clinical trials for patients with advanced non-small cell lung cancer. AstraZeneca aims to combine Summit's drug with its own portfolio of targeted antibody-drug conjugates to treat a wider range of tumor types that resist first-generation PD-1 agents. The pharmaceutical company also just opened a $1B, 570,000 square-foot R&D facility in Kendall Square, Cambridge, allocating roughly 20% of the site's investment toward robotics, continuous automation, and agentic AI. "The idea is to really leverage AI to invent new medicines faster, but also invest in robotics to simplify and accelerate the process of discovering and developing molecules throughout the preclinical phase in particular." — Pascal Soriot